



## Final Appraisal Recommendation

### Tapentadol prolonged release (Palexia<sup>®</sup> SR<sup>▼</sup>)

Submission by:  
Grunenthal Ltd

Advice No: 1511 – November 2011

#### Recommendation of AWMSG

Tapentadol prolonged release (Palexia<sup>®</sup> SR<sup>▼</sup>) is recommended as an option for restricted use within NHS Wales, only in the following subpopulation within its licensed indication:

- Patients with severe chronic pain, in whom morphine sulphate modified release has failed to provide adequate pain control or is not tolerated.

Tapentadol prolonged release (Palexia<sup>®</sup> SR<sup>▼</sup>) is not recommended for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics, outside of the subpopulation described above.

AWMSG is of the opinion that tapentadol prolonged release (Palexia<sup>®</sup> SR<sup>▼</sup>) should be initially prescribed by a specialist\*. Prescribing may be continued in primary care with appropriate communication and specialist input.

\*Specialist implies specialist team or GP with special interest (GPwSI) with appropriate accreditation from the specialist faculty.

#### Additional notes:

This recommendation only applies to the use of tapentadol prolonged release tablets (Palexia<sup>®</sup> SR<sup>▼</sup>). A separate AWMSG recommendation regarding [tapentadol film-coated tablets \(Palexia<sup>®</sup>\)](#) is available from the AWMSG website.

In reaching this recommendation AWMSG took account of the [AWMSG Secretariat Assessment Report](#), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, [clinical expert opinion](#), lay/patient/carer perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: